.jpg)
Albert D. Friesen
From Wikipedia, the free encyclopedia
Albert David "Bert" Friesen, OC OM (born May 19, 1947) is a Canadian biotechnologist involved in biotechnology innovation.[1] His biotechnology career began as the first full-time employee of the Winnipeg Rh Institute, where he later became president and CEO, and led the development of WinRho, one of Canada's first successful biotech products.[2]
Education
Albert Friesen went to the University of Manitoba and earned a Ph.D. in protein chemistry.[3]
Career
In 1987, Dr. Friesen was a founder and the company’s first board of directors Chairman at the Industrial Biotechnology Association of Canada (IBAC) which is now known as BIOTECanada.[4]
In 1997, Friesen founded Medicure, which sells a large number of cardiovascular products. In 2020, Medicure purchased Marley Drug and the company can now sell medications directly to patients.[4]
From 2014-2017, Friesen was chair on the International board of MEDA (Mennonite Economic Development Associates).[4]
In March 2023, Dr. Friesen was awarded Outstanding Leadership in Bioscience of the Year at the Annual Bioscience Association Manitoba (BAM) gala.[4]
He was made an Member of the Order of Canada in 2025.[5]
.svg){kind=small}
